Article
Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22
The Boston Society in collaboration with Harvard Medical School is bringing together the top Acute Myeloid Leukemia (AML) experts for a power-packed one day conference to deliberate upon AML from varied perspectives.
The Boston Society in collaboration with Harvard Medical School is bringing together the top Acute Myeloid Leukemia (AML) experts for a power-packed one day conference to deliberate upon AML from varied perspectives.
Gone are the days of running around the city for days at a national conference hunting for the topics of your interest. Instead, this one-day VIRTUAL EVENT for AML has managed to bring together the Who-is-Who from the world of AML from different sectors in the spirit of ‘Academia-Public-Industry’ partnership. This AML Special Conference will deliberate upon Acute Myeloid Leukemia and Myelodysplastic Syndrome. https://www.bostonsociety.org/AML/
Dr. Vas Narasimhan, CEO, Novartis will deliver the keynote address to share his vision of‘Reimagining Medicine to Bring New Therapies for our Patients’
The power-packed panel includes: Manipulating the Microenvironment for AML Therapies (GMI 1271): Daniel J. DeAngelo, MD, PhD, Chief, Division of Leukemia, Dana Farber Cancer Institute, Professor of Medicine at Harvard Medical School; Update in CAR-T and Other Cell Therapies for AML: Gail J. Roboz, MD, Professor of Medicine & Director, Clinical Translational Leukemia Program, Weill Medical College, Cornell University; Immunomodulatory Therapeutic Strategies (PD1/PDL1, CD47, CD70); David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center & Research Institute; Targeted Therapy for Pediatric AML: Yana Pikman, MDAttending Physician, Pediatric Heme/Oncology, Dana Farber Cancer Institute, Harvard Medical School;From Disney to Doxorubicin: Childhood Cancer Perspective from a Medical Dad:Andrew J. Herber, PA-C, Mayo Clinic Hospital; SARS-CoV-2 Infections in Malignancy: Vivek Naranbhai, MD,PhD, Clinical Fellow in Medicine, Dana Farber Cancer Institute; Updates in MDS Treatment: Andrew M. Brunner, MD, Asst. Professor, Harvard Medical School, Assistant, Center for Leukemia, Massachusetts General Hospital; Transplant in the Context of MDS Patients: Corey Cutler, MD, MPH, FRCPC, Medical Director, Adult Stem Cell Transplantation Program, Director Clinical Research, Stem Cell Transplantation, Associate Professor of Medicine, Harvard Medical School.
Lori A. Ehrlich, MD, PhD, Medical Officer at Food and Drug Administration (FDA)will share FDA Perspective on New Therapy Development for AML.
The Boston Society has been rendering a public service by facilitating world-class conferences brought to the participants at virtually a negligible cost such that science is more affordable.
The Medical Symposium is a forum for exchanging information, discussion of treatment strategies, and clinical development. The symposium is a gathering of experts in the field and was developed to address the difficulties in clinical development and patient treatment for specific indications, to fill the gap between researchers and clinicians as drugs transition from the proof-of-concept stage into clinical trials.
This national conference is open to all interested who can register at: https://www.bostonsociety.org/AML/
